An influential Republican lawmaker long known for blocking marijuana reforms, particularly in Washington, D.C., faces an unexpected political threat after Maryland’s House of Delegates advanced a new congressional map that could make his seat vulnerable this November.
Earlier this week, the Maryland State House approved HB 488, a redistricting plan that analysts say would tilt Maryland’s 1st Congressional District in favor of Democrats for the first time since the state’s previous map was drawn in 2011.
The measure follows a recommendation from a five-member gubernatorial advisory committee and now proceeds to the state Senate, Marijuana Moment reports.
Political observers say the change could imperil Maryland Republican Rep. Andy Harris, the only Republican in the state’s eight-member U.S. House delegation.
Harris has used his committee roles and procedural levers to oppose marijuana reform at the federal level consistently and to restrict local autonomy in the nation’s capital.
Since 2014 — the same year District voters approved legal recreational cannabis — an appropriations provision widely known as the “Harris rider” has barred the District of Columbia from using local funds to implement a regulated market for adult-use marijuana.
That rider, repeatedly attached to Financial Services and General Government appropriations bills, has survived under both Democratic and Republican congressional majorities and administrations, frustrating D.C. leaders and advocates who argue the city’s voters should be able to set their own cannabis policy.
As chair of a House appropriations subcommittee that oversees agriculture and related agencies, Harris has additionally opposed federal rescheduling of cannabis, criticized the 2018 Farm Bill’s hemp provisions as a “loophole,” and resisted measures that would allow banks to serve state-legal marijuana businesses.
He has publicly questioned the authority of a president to unilaterally reschedule the drug and framed rescheduling efforts as a public-health risk. These comments have drawn pushback from reform advocates and some federal health officials.
The Congressional Research Service has noted that if cannabis were rescheduled to Schedule III under the Controlled Substances Act, the District government would be able, under local law, to authorize commercial recreational sales, regulate a market, and levy marijuana taxes — a potential path around the rider’s prohibitions.
However, the rider’s language also bars D.C. from using funds to legalize or reduce penalties for “any tetrahydrocannabinol derivative,” a phrase whose legal meaning remains unclear and could complicate implementation even after rescheduling.
Harris has signaled he would challenge any enacted redistricting map in court if it threatens his reelection prospects.
Even if the new map is ultimately adopted and he is defeated, experts caution that removing Harris from his appropriations perch would not automatically guarantee federal cannabis reform; other members share his opposition, and Congress as a whole remains divided.
Still, losing a staunch and strategically placed opponent could shift momentum in favor of advocates, particularly on measures affecting D.C. autonomy.
The redistricting bill’s passage in the House intensifies a high-stakes campaign season in Maryland.
With cannabis policy intertwined with questions of representation and local control, voters in the reconfigured district will confront both the national debate over marijuana and a local contest that could reshape who shepherds appropriations decisions affecting the nation’s capital.
